meningococcal (group B) vaccine
Trade name: Bexsero
Vaccineapproved
Approved
Jan 23, 2015
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. — Wikipedia
Clinical trial activity
53 trials · 26 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
42
Phase 3
24
Phase 4
6
Earliest trial started Jul 1, 2002 (NCT00137917)
Timeline
Indications
Approved for
Studied for
- Autoimmune Diseases · Phase 4
- Communicable Diseases · Phase 2
- Gonorrhea · Phase 3
- Healthy Volunteers · Phase 3
- Herpes Genitalis · Phase 1/Phase 2
- HIV · Phase 4
- HIV Infections · Phase 4
- Immune System Diseases · Phase 4
- Infant, Premature, Diseases · Phase 4
- Meninges · Phase 3
- Meningitis · Phase 3
- Meningitis, Meningococcal · Phase 4
- Meningococcal Infections · Phase 4
- Meningococcal Vaccines · Phase 3
- Neisseria meningitidis · Phase 2
- Respiratory Syncytial Virus Infections · Phase 1
- Risk-Taking · Phase 3
- Splenectomy · Phase 3
- Transgender Persons · Phase 4
- Unsafe Sex · Phase 3
- Vaccination · Phase 4
Mechanism of action
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
Approval history
- approvedJan 23, 2015
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMeningococcal vaccine ↗
Also known as
- menb
- menbvac
- recombinant neisseria meningitidis group-b nhba fusion protein /recombinant neisseria meningitidis group-b nada protein /recombinant neisseria meningitidis group b fhbp fusion protein /outer membrane vesiclesfrom neisseria meningitidis group-b strain nz98 / 254 measured as amount of total protein containing the pora p1.4
- rmenb
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07252804 | Phase 4 | Jan 1, 2026 | Insituto Adolfo Lutz, University of Sao Paulo |
| NCT06995430 | Phase 3 | Jul 7, 2025 | GlaxoSmithKline |
| NCT06832514 | Phase 4 | Jan 31, 2025 | Ghent University |
| NCT06446752 | Phase 3 | Aug 31, 2024 | Bill and Melinda Gates Foundation, University of the Witwatersrand, University of Washington |
| NCT06113198 | Phase 4 | Nov 15, 2023 | GlaxoSmithKline |
| NCT06025487 | Phase 2 | Oct 1, 2023 | Medical University of Vienna |
| NCT06033261 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2023 | Moderna Therapeutics |
| NCT05082285 | Phase 2 | Nov 29, 2021 | GlaxoSmithKline |
| NCT04886154 | Phase 1/Phase 2 (Phase 2) | Jun 14, 2021 | GlaxoSmithKline |
| NCT04707391 | Phase 3 | Jan 25, 2021 | GlaxoSmithKline |
| NCT04597424 | Phase 3 | Dec 31, 2020 | Government of France |
| NCT04645966 | Phase 2 | Nov 24, 2020 | Pfizer |
| NCT04502693 | Phase 3 | Aug 14, 2020 | GlaxoSmithKline |
| NCT04297436 | N/A | Jun 30, 2020 | University of Oxford, Wellcome Trust |
| NCT04166656 | Phase 3 | Feb 29, 2020 | Assistance Publique - Hôpitaux de Paris, EUCLID, Innovative clinical research network in vaccinology (I-REIVAC), Institut Pasteur, University of Paris |
| NCT04084769 | Phase 3 | Sep 3, 2019 | Sanofi-Aventis |
| NCT03636906 | Phase 1 | Apr 1, 2019 | GlaxoSmithKline |
| NCT03682939 | Phase 4 | Sep 30, 2018 | University of London |
| NCT03621670 | Phase 3 | Jul 27, 2018 | GlaxoSmithKline |
| NCT03587207 | Phase 2 | Jul 9, 2018 | GlaxoSmithKline |
Showing 20 of 53 trials
Page 1 / 3
Organizations
Research & Development (26)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 21 | 18 | 2 | 2006 |
| GlaxoSmithKline | For profit | 17 | 15 | 4 | 2002 |
| Public Health England | Government | 5 | 2 | 2 | 2005 |
| Pfizer | For profit | 4 | 4 | 1 | 2008 |
| University of London | Academic/Hospital | 3 | 2 | 2 | 2015 |
| Health Protection Agency, United Kingdom | Government | 2 | 0 | 1 | 2005 |
| Institut Pasteur | Academic/Hospital | 2 | 0 | 1 | 2012 |
| University of Oxford | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
| EUCLID | For profit | 1 | 0 | 1 | 2020 |
| Ghent University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Government of France | Government | 1 | 1 | 1 | 2020 |
| Innovative clinical research network in vaccinology (I-REIVAC) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Insituto Adolfo Lutz | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Medical University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2023 |
| MeningitisNow | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Moderna Therapeutics | For profit | 1 | 1 | 1 | 2023 |
| Rouen Normandy University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2019 |
26 organizations
Page 1 / 2